Semaglutide

weight loss

Semaglutide (GLP-1 Receptor Agonist)

Mechanism of Action

A GLP-1 receptor agonist that slows gastric emptying, reduces appetite, improves insulin sensitivity, and promotes satiety. FDA-approved as Ozempic (diabetes) and Wegovy (weight management).

Common Doses

250mcg

1x weeklysubcutaneous

500mcg

1x weeklysubcutaneous

1mg

1x weeklysubcutaneous

Common Protocols

Dose Escalation16-20 weeks

Start 250mcg/week, increase by 250mcg every 4 weeks

Safety Notes

FDA-approved. Common side effects: nausea (36.9%), diarrhea, vomiting. Risk of pancreatitis, gallbladder disease. Weight regain common after discontinuation.

Legal Status

United States

FDA Approved

Australia

TGA Approved

United Kingdom

MHRA Approved

Ready to track this peptide?

Start Experiment

This information is for educational purposes only. N1X does not recommend, endorse, or facilitate access to any substance. Always consult a qualified healthcare provider before starting any protocol.